Mineralocorticoid receptor p.I180V polymorphism: Association with body mass index and LDL-cholesterol levels
- 44 Downloads
Background/Aims: Aldosterone and the mineralocorticoid receptor (MR) play a major role in sodium balance and blood pressure control. They are also involved in adipocyte metabolism. The aim of this study was to analyze the association between the MR p.I180V polymorphism with hypertension and markers of cardiovascular risk. Design and methods: Case-control study nested within a cohort of 2063 subjects followed since birth to date. All subjects (age 23–25 yr old) from the entire cohort with systolic and diastolic hypertension (no.=126) were paired with 398 normotensive controls. MR p. I180V genotype association with anthropometric and biochemical markers of cardiometabolic risk was tested. Results: There was a significant association of the MR p. I180V genotype with body mass index (BMI) and LDL-cholesterol level (p<0.01). Hypertensive subjects carrying the polymorphic G allele (AG or GG genotypes) presented significantly higher BMI (30.0±6.0 vs 28.7±5.6 kg/m2; p<0.01) and higher LDL-cholesterol (139.9±60.3 vs 109.9±35.5 mg/dl; p<0.01). The frequency of the polymorphism MR p.I180V was similar between hypertensive subjects and controls (p=0.15). Conclusions: The MR p.I180V polymorphism seems to be associated with cardiovascular risk factors including BMI and LDL-cholesterol levels. This original in vivo finding reinforces the role of MR in adipocyte biology and in cardiovascular disease.
KeywordsCardiometabolic risk hypertension mineralocorticoid receptor obesity polymorphism
Unable to display preview.
- 1.Zennaro MC, Lombès M. Mineralocorticoid resistance. Trends Endocrinol Metab 2004, 15: 264–70.CrossRef
- 2.Verrey F, Pearce D, Pfeiffer R, et al. Pleiotropic action of aldosterone in epithelia mediated by transcription and post-transcription mechanisms. Kidney Int 2000, 57: 1277–82.CrossRef
- 3.Geller DS. Mineralocorticoid resistance. Clin Endocrinol (Oxf) 2005, 62: 513–20.CrossRef
- 4.Riepe FG, Finkeldei J, de Sanctis L, et al. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 2006, 91: 4552–61.CrossRef
- 5.Fernandes-Rosa FL, de Castro M, Latronico AC, et al. Recurrence of the R947X mutation in unrelated families with autosomal dominant pseudohypoaldosteronism type 1: evidence for a mutational hot spot in the mineralocorticoid receptor gene. J Clin Endocrinol Metab 2006, 91: 3671–5.CrossRef
- 6.Sartorato P, Lapeyraque AL, Armanini D, et al. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 2003, 88: 2508–17.CrossRef
- 7.Geller DS, Rodriguez-Soriano J, Vallo Boado A, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998, 19: 279–81.CrossRef
- 8.Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289: 119–23.CrossRef
- 9.Lifton RP. Molecular genetics of human blood pressure variation. Science 1996, 272: 676–80.CrossRef
- 10.Wilson FH, Disse-Nicodème S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293: 1107–12.CrossRef
- 11.Freitas SR, Cabello PH, Moura-Neto RS, et al. Analysis of renin-angiotensin-aldosterone system gene polymorphisms in resistant hypertension. Braz J Med Biol Res 2007, 40: 309–16.CrossRef
- 12.Tobin MD, Raleigh SM, Newhouse S, et al. Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation 2005, 112: 3423–9.CrossRef
- 13.Su YR, Menon AG. Epithelial sodium channels and hypertension. Drug Metab Dispos 2001, 29: 553–6.
- 14.Mottl AK, Shoham DA, North KE. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: A HugE review. Genet Med 2008, 10: 560–74.CrossRef
- 15.Moraes CF, Souza ER, Souza VC, et al. A common polymorphism in the renin angiotensin system is associated with differential outcome of antihypertensive pharmacotherapy prescribed to Brazilian older women. Clin Chim Acta 2008, 396: 70–5.CrossRef
- 16.Conen D, Glynn RJ, Buring JE, et al. Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study. J Hypertens 2008, 26: 1780–6.CrossRef
- 17.Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 2002, 970: 89–100.CrossRef
- 18.Nagase M, Matsui H, Shibata S, et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50: 877–83.CrossRef
- 19.Zennaro MC, Le Menuet D, Viengchareun S, et al. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest 1998, 101: 1254–60.CrossRef
- 20.Viengchareun S, Penfornis P, Zennaro MC, et al. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab 2001, 280: 640–9.
- 21.Caprio M, Fève B, Claës A, et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21: 2185–94.CrossRef
- 22.Arai K, Nakagomi Y, Iketani M, et al. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum Genet 2003, 112: 91–7.CrossRef
- 23.DeRijk RH, Wüst S, Meijer OC, et al. A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J Clin Endocrinol Metab 2006, 91: 5083–9.CrossRef
- 24.Cardoso VC, Simões VM, Barbieri MA, et al. Profile of three Brazilian birth cohort studies in Ribeirão Preto, SP and São Luís, MA. Braz J Med Biol Res 2007, 40: 1165–76.CrossRef
- 25.Barbieri MA, Bettiol H, Silva AA, et al. Health in early adulthood: the contribution of the 1978/79 Ribeirão Preto birth cohort. Braz J Med Biol Res 2006, 39: 1041–55.CrossRef
- 26.Bustos P, da Silva AA, Amigo H, et al. Metabolic syndrome in young adults from two socioeconomic Latin American settings. Nutr Metab Cardiovasc Dis 2007, 17: 581–9.CrossRef
- 27.Mion D Jr, Machado CA, Gomes MAM, et al. IV Brazilian Guidelines on Arterial Hypertension. Arq Bras Cardiol 2004, 82: 1–22.
- 28.Hense HW, Koivisto AM, Kuulasmaa K, et al. Assessment of blood pressure measurement quality in the baseline surveys of the WHO MONICA project. J Hum Hypertens 1995, 9: 935–46.
- 29.Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289: 2560–72.CrossRef
- 30.Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.CrossRef
- 31.Arai K, Tsigos C, Suzuki Y, et al. Physiological and molecular aspects of mineralocorticoid receptor action in pseudohypoaldosteronism: a responsiveness test and therapy. J Clin Endocrinol Metab 1994, 79: 1019–23.
- 32.Ludwig M, Bolkenius U, Wickert L, et al. Common polymorphisms in genes encoding the human mineralocorticoid receptor and the human amiloride-sensitive sodium channel. J Steroid Biochem Mol Biol 1998, 64: 227–30.CrossRef
- 33.Silva LM, Silva RA, Silva AA, et al. Racial inequalities and perinatal health in the southeast region of Brazil. Braz J Med Biol Res 2007, 40: 1187–94.CrossRef
- 34.Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal 2007, 530: 5–12.
- 35.Fuse H, Kitagawa H, Kato S. Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Mol Endocrinol 2000, 14: 889–99.CrossRef
- 36.Tallec LP, Kirsh O, Lecomte MC, et al. Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol Endocrinol 2003, 17: 2529–42.CrossRef
- 37.Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005, 10: 15–22.CrossRef
- 38.Spencer RL, Kim PJ, Kalman BA, Cole MA. Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology 1998, 139: 2718–26.
- 39.Young EA, Lopez JF, Murphy-Weinberg V, et al. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 1998, 83: 3339–45.
- 40.Heuser I, Deuschle M, Weber A, et al. The role of mineralocorticoid receptors in the circadian activity of the human hypothalamus-pituitary-adrenal system: effect of age. Neurobiol Aging 2000, 21: 585–9.CrossRef